Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tomaralimab, vb-201 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 125 Parkinson's papers of 15,858 | 0.36 |
| pathways Reactome | 12 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2385
Sealed predictions
- TLR2 in dopamine neurons, braak-0.01 (p 0.982) → +0.74 (p 0.023)receipt 2392
Swarm cases
receipt 2392: TLR2 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.132, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.132, n 18). could be the mix.
- skeptic
- leave-one-out range +0.30 to +0.55, sign flips 0; without severely affected donors +0.37 (p 0.132, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TLR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts